Niagen Bioscience's Real Headline Isn't the Summit — It's the Growth Stall

Niagen Bioscience, the healthy-aging supplement company that most investors still know by its old name, ChromaDex, is scheduled to present this month at Canaccord Genuity's "Well Summit," a consumer-health investor conference in New York centered on companies like this one. Chief executive Rob Fried and chief financial officer Ozan Pamir will be making the pitch.

For a roughly $245-million micro-cap trading under the Nasdaq ticker NAGE, a conference invitation is routine investor-relations work — the financial-world equivalent of a vendor paying for a booth. By itself it rarely does anything to the price. What is worth your time is what the company would actually be selling, because behind the summit fanfare the numbers have changed shape over the past year.

The number the conference won't lead with

A year ago, Niagen looked like a breakout. Full-year 2025 net sales rose 30% to $129.4 million, net income more than doubled to $17.4 million, and adjusted EBITDA reached $20.4 million, with the quarter-to-quarter trajectory compounding nicely through the fall.

Then the growth ran into a wall. Put the recent quarters side by side and the direction is unmistakable: up 33% in the third quarter of 2025, up 16% in the fourth, up 3% in the first quarter of 2026, and then down roughly 4% in the second. Second-quarter net sales came in at $29.8 million, against $31.1 million a year earlier.

The deterioration runs deeper than revenue. In that same quarter net income fell to $1.0 million from $3.6 million, adjusted EBITDA to $3.0 million from $5.0 million, and first-half operating cash flow tumbled to $1.6 million from $9.1 million. That is a company that compounded sales at 30% in 2025 and ended the first half of 2026 essentially flat, with profits compressing sharply while management guided operating expenses higher. That is the real headline hiding behind the summit invite.

The bear fact that has to be answered

The company has named the source of the problem itself — and it is the load-bearing question for anyone tempted to call the dip a contrarian buy. On the second-quarter call, management said the ingredient business, the arm that sells Niagen as a bulk ingredient to other brands, would be lower than a year earlier for all of 2026 because of "a more competitive landscape." The NAD+ category that powered the 2025 boom has drawn more entrants chasing the same ingredient economics.

For a small stock whose entire thesis rests on a proprietary moat, that sentence is exactly what separates "there's competition" from "the advantage is under real pressure." The partly reassuring part is where the pressure is landing. Tru Niagen, the branded consumer franchise, accounted for $24.2 million of the $29.8 million in second-quarter sales, and the company's own website grew 23% year over year, with management guiding full-year e-commerce up 10% to 15%. The slowdown is concentrated in the ingredient channel, not in the consumer brand the company actually owns. That distinction is the difference between a moat under stress and one that has cracked.

What the pivot has to prove

Management is spending this slowdown positioning for two bigger things, both pitched as "2027" stories. One is Niagen Plus, a medical-angle platform that sells pharmaceutical-grade Niagen as an at-home injection kit through a telehealth program — an attempt to move the brand from a supplement bottle to a clinician-directed therapy. The other is a genuine drug program: NB4168, a next-generation NAD+ precursor aimed at Ataxia-Telangiectasia, a rare pediatric genetic disease with no approved treatment, which has already pulled in FDA Rare Pediatric Disease designation and European orphan status.

Neither is revenue today, and pharmaceuticals in particular are years and failure-options away. But back that optionality with a $66.7 million cash balance, no debt, and $2.8 million of stock buybacks in the quarter, and the bull case has a foundation even if the near-term numbers don't.

Now the honest part, because this is where I'll resist the reflex to call every fall a bargain. Here the fundamentals genuinely weakened: growth stalled, profits compressed, and the ingredient headwind is the company's own words, not speculation. At roughly $245 million in market value on $129 million of trailing sales — under $180 million in enterprise value once the cash is netted out — the stock trades near 2x sales. That is moderate for a consumer company and not cheap for one that has stopped growing.

So the summit is noise, and the market is not obviously wrong about the core supplement business today. What the price is really asking you to underwrite is the 2027 narrative: whether the consumer brand's momentum holds while the ingredient pressure is contained, and whether telehealth and pharma stop being slides. That is a real bet, but it is a bet on promises the balance sheet hasn't cashed yet — and a conference appearance, however respectable the host, is not evidence one way or the other.